Title:A Case Report of Chronic Inflammatory Demyelinating Polyneuropathy
following COVID-19 Vaccination
Volume: 20
Issue: 1
Author(s): Hedyieh Karbasforooshan, Shahram Amini, Reza Boostani, Pourandokht Mousavian and Hesamoddin Hosseinjani*
Affiliation:
- Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
Keywords:
COVID-19, chronic inflammatory demyelinating polyneuropathy, vaccine, peripheral neuropathy, Guillain-barre syndrome.
Abstract:
Introduction: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a peripheral
polyneuropathy. Chronic damage to neuronal myelin by the immune system results in inflammation
and demyelination of the peripheral nervous system. Several side effects have been reported
with Coronavirus disease 2019 (COVID-19) vaccines. There are some reports of vaccineinduced-
CIDP. In this study, we described the occurrence of CIDP in a patient with a history of receiving
the first dose of a COVID-19 vaccine, Sputnik V.
Case Report: We presented a patient receiving the COVID-19 vaccine Sputnik V two weeks before
progressive flaccid tetraparesis and dysautonomia. He was first diagnosed with Guillain-
Barre Syndrome (GBS). Two episodes of worsening the weakness occurred within 8 weeks
from the onset of the disease, and the treatment was repeated as GBS-Treatment-related Fluctuations
(TRF) and relapse. Also, a few relapses happened eight weeks after the disease's onset.
Hence, he was diagnosed with “acute-onset CIDP”. The patient received several intravenous immunoglobulin
(IVIG) courses as maintenance therapy. No further deterioration was reported during
the follow-up.
Conclusion: Post-vaccination GBS is a known phenomenon. However, there are several reports
of vaccine-induced-CIDP. This is the first reported case of acute-onset CIDP associated with the
Sputnik V vaccine in Iran. Subsequent studies are required to determine the definite relationship
between COVID-19 vaccination and CIDP.
